Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability
Open Access
- 1 July 2012
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 7, 3951-3959
Abstract
Ovarian cancer is one of the leading causes of cancer death for women throughout the Western world. Kaempferol, a natural flavonoid, has shown promise in the chemoprevention of ovarian cancer. A common concern about using dietary supplements for chemoprevention is their bioavailability. Nanoparticles have shown promise in increasing the bioavailability of some chemicals. Here we developed five different types of nanoparticles incorporating kaempferol and tested their efficacy in the inhibition of viability of cancerous and normal ovarian cells. We found that positively charged nanoparticle formulations did not lead to a significant reduction in cancer cell viability, whereas nonionic polymeric nanoparticles resulted in enhanced reduction of cancer cell viability. Among the nonionic polymeric nanoparticles, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) nanoparticles incorporating kaempferol led to significant reduction in cell viability of both cancerous and normal cells. Poly(DL-lactic acid-co-glycolic acid) (PLGA) nanoparticles incorporating kaempferol resulted in enhanced reduction of cancer cell viability together with no significant reduction in cell viability of normal cells compared with kaempferol alone. Therefore, both PEO-PPO-PEO and PLGA nanoparticle formulations were effective in reducing cancer cell viability, while PLGA nanoparticles incorporating kaempferol had selective toxicity against cancer cells and normal cells. A PLGA nanoparticle formulation could be advantageous in the prevention and treatment of ovarian cancers. On the other hand, PEO-PPO-PEO nanoparticles incorporating kaempferol were more effective inhibitors of cancer cells, but they also significantly reduced the viability of normal cells. PEO-PPO-PEO nanoparticles incorporating kaempferol may be suitable as a cancer-targeting strategy, which could limit the effects of the nanoparticles on normal cells while retaining their potency against cancer cells. We have identified two nanoparticle formulations incorporating kaempferol that may lead to breakthroughs in cancer treatment. Both PEO-PPO-PEO and PLGA nanoparticle formulations had superior effects compared with kaempferol alone in reducing cancer cell viability.Keywords
This publication has 37 references indexed in Scilit:
- Temporal Control over Cellular Targeting through Hybridization of Folate-targeted Dendrimers and PEG-PLA NanoparticlesBiomacromolecules, 2012
- Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathwayFood Chemistry, 2012
- Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathwayFood Chemistry, 2011
- Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activityBiochemical Pharmacology, 2010
- Nanochemoprevention: Sustained Release of Bioactive Food Components for Cancer PreventionNutrition and Cancer, 2010
- Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivoAnti-Cancer Drugs, 2010
- Kaempferol Inhibits Angiogenesis and VEGF Expression Through Both HIF Dependent and Independent Pathways in Human Ovarian Cancer CellsNutrition and Cancer, 2009
- Introducing Nanochemoprevention as a Novel Approach for Cancer Control: Proof of Principle with Green Tea Polyphenol Epigallocatechin-3-GallateCancer Research, 2009
- Flavonoids and ovarian cancer risk: A case–control study in ItalyInternational Journal of Cancer, 2008
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003